Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00240045
Status:
COMPLETED
Last Update Posted:
2007-12-06
First Post:
2005-10-13
Brief Title:
The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
Sponsor:
University of Alberta
Organization:
University of Alberta
Study Overview
Official Title:
The Use of Midodrine Octreotide and Albumin in Refractory Ascites
Status:
COMPLETED
Status Verified Date:
2005-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are mediated in part by diminished circulatory volume and that treatment with midodrine octreotide and albumin can improve renal and patient outcomes by restoring effective circulating volume and systemic perfusion
Our primary objective is to assess change in creatinine clearance using inulin We will enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and exclusion criteria are satisfied They will be treated for 1 month with octreotide LAR albumin and midodrine Renal serum and neurohormonal parameters will be measured before during and after initiation of drug and compared
Our primary objective is to assess change in creatinine clearance using inulin We will enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and exclusion criteria are satisfied They will be treated for 1 month with octreotide LAR albumin and midodrine Renal serum and neurohormonal parameters will be measured before during and after initiation of drug and compared
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None